SCHEMBL30011232

SCHEMBL30011232

CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CS)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)O)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 5/20 0.48
▸ FNTB P49356 5/20 0.48
▸ ACE P12821 1/20 0.48
▸ BACE1 P56817 10/20 0.44
▸ CTSD P07339 2/20 0.43
▸ BACE2 Q9Y5Z0 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30011243 1.00 FNTA (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL30010811 1.00 FNTA (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL30011210 1.00 FNTA (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL30010590 1.00 FNTA (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL30011199 1.00 FNTA (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL30288030 0.95 ACE (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL30288010 0.95 ACE (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL29714714 0.93 FNTA (0.48) FNTAFNTBACEBACE1CTSD
SCHEMBL29874133 0.92 ACE (0.56) FNTAFNTBACE
SCHEMBL30010989 0.92 ACE (0.56) FNTAFNTBACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250345411-A1 VACCINATION IN NEWBORNS AND INFANTS CureVac SE (DE) 2025-11-13 — — US disclosed
US-20250345410-A1 VACCINATION IN NEWBORNS AND INFANTS CureVac SE (DE) 2025-11-13 — — US disclosed
US-12390520-B2 Vaccination in newborns and infants Cure Vac SE (DE) 2025-08-19 — — US disclosed
US-20240390478-A1 VACCINATION IN ELDERLY PATIENTS CureVac SE (DE) 2024-11-28 — — US disclosed
US-12036277-B2 Vaccination with mRNA-coded antigens CureVac SE (DE) 2024-07-16 — — US disclosed
US-20240197857-A1 VACCINATION WITH mRNA-CODED ANTIGENS CureVac SE (DE) 2024-06-20 — — US disclosed
US-11975064-B2 Vaccination with mRNA-coded antigens CureVac SE (DE) 2024-05-07 — — US disclosed
US-20230302146-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO CureVac SE (DE) 2023-09-28 — — US disclosed
US-20230285594-A1 COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION CureVac SE (DE) 2023-09-14 — — US disclosed
US-20230233662-A1 VACCINATION IN NEWBORNS AND INFANTS CureVac SE (DE) 2023-07-27 — — US disclosed
US-11672856-B2 Vaccination in newborns and infants CureVac SE (DE) 2023-06-13 — — US disclosed
US-11478552-B2 Hybrid carriers for nucleic acid cargo CUREVAC AG (DE) 2022-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11478552-B2 Hybrid carriers for nucleic acid cargo HNRNPH1, HNRNPH3, SNRPE FNTA 1398/4885FNTB 838/4885ACE 4699/4885
US-20250345410-A1 VACCINATION IN NEWBORNS AND INFANTS HLA-DRB1, TLR3, TLR9 FNTA 2481/4885FNTB 782/4885ACE 4227/4885
US-20230302146-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO HNRNPH1, HNRNPH3, SNRPE FNTA 1398/4885FNTB 838/4885ACE 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback